Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: a clinical and imaging comparative study

December 2009
International Journal of Advances in Rheumatology;2009, Vol. 7 Issue 4, p125
Academic Journal
Ultrasound analysis of rheumatoid arthritis patients in remission with combination therapy demonstrates persistent synovitis, a finding that has implications for both therapeutic mechanism and long-term outcomes in these patients.


Related Articles

  • Biologic Rheumatoid Arthritis Therapies. Levesque, Marc C. // BioDrugs;2012, Vol. 26 Issue 2, p65 

    Rheumatoid arthritis (RA) affects an estimated 1.3 million Americans and is a complex inflammatory disease associated with synovitis and joint destruction. The development of biologic disease-modifying antirheumatic drugs (DMARDs) that target specific mediators of inflammation has led to several...

  • Rheumatoid Arthritis.  // Current Medical Literature: Rheumatology;2009, Vol. 28 Issue 4, p107 

    The article presents abstracts on rheumatoid arthritis (RA) which include the effectiveness of golimumab in the treatment of active RA following treatment with tumour necrosis factor alpha inhibitors, the effectiveness of high-intensity exercise program in patients with RA and the efficacy and...

  • Adalimumab A Review of its Use in Rheumatoid Arthritis. Bang, Lynne M.; Keating, Gillian M. // BioDrugs;2004, Vol. 18 Issue 2, p121 

    Adalimumab (Humira®) is a recombinant, fully human IgG1 monoclonal antibody that binds specifically to tumor necrosis factor (TNF)-α, thereby neutralizing the activity of the cytokine. Subcutaneous adalimumab has been investigated in well designed trials in patients with active rheumatoid...

  • Effectiveness of Golimumab in Clinical Management of Patients with Rheumatoid Arthritis. Shono, Eisuke // Drugs in R&D;2013, Vol. 13 Issue 1, p95 

    Background and Objectives: Limited data are available regarding the use of golimumab (100 mg) every 4 weeks, with or without methotrexate (MTX). The aim of this retrospective analysis was to evaluate the effectiveness and safety of golimumab following usual clinical practice in Japanese patients...

  • Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review. Besada, Emilio // Patient Preference & Adherence;Aug2014, Vol. 8, p1051 

    Treatment of rheumatoid arthritis (RA) was revolutionized during the last decade with the development of new biologic disease-modifying anti-rheumatic drugs (DMARDs) enabling the targeting of immune cells and cytokines other than tumor necrosis factor (TNF). Subcutaneous formulations of the...

  • Leflunomide in systemic onset juvenile idiopathic arthritis. Jahan, Afsana; Dewan, Vivek; Yadav, Tribhuvan // Indian Pediatrics;Sep2012, Vol. 49 Issue 9, p750 

    Methotrexate, the mainstay of treatment in Juvenile idiopathic arthritis, might not be effective in a few patients of polyarticular and systemic onset juvenile idiopathic arthritis. Use of biologicals like TNF-α blockers, the next line of preferred drugs is constrained by the high cost. We...

  • Abatacept In Focus. Cohen, Marc // Internet Journal of Rheumatology;2007, Vol. 3 Issue 1, p1 

    There have been considerable advances in the treatment of rheumatoid arthritis. However, many patients are found to be refractory to traditional disease-modifying antirheumatic drugs and the newer anti-cytokine therapies. Agents such as abatacept and rituximab now offer exciting new options for...

  • Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. Nakashima, Yasuharu; Kondo, Masakazu; Harada, Hiroshi; Horiuchi, Takahiko; Ishinishi, Takashi; Jojima, Hiroshi; Kuroda, Koji; Miyahara, Hisaaki; Nagamine, Ryuji; Nakashima, Hitoshi; Otsuka, Takeshi; Saikawa, Isao; Shono, Eisuke; Suematsu, Eiichi; Tsuru, Tomomi; Wada, Ken; Iwamoto, Yukihide // Modern Rheumatology (Springer Science & Business Media B.V.);Aug2010, Vol. 20 Issue 4, p343 

    We retrospectively observed the clinical efficacy and safety of tocilizumab (TCZ) in 74 patients with rheumatoid arthritis (RA) at 13 hospitals, without any restrictions on disease duration or stage, treatment history, and other influencing factors. TCZ was infused by the approved method, and...

  • Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.  // International Journal of Advances in Rheumatology;2011, Vol. 9 Issue 3, p102 

    The article discusses research which utilized data from the British Society for Rheumatology Biologics Register (BSRBR). It references a study by M. M. Soliman et al, published in "Annals of Rheumatic Diseases." The study revealed that patients receiving methotrexate were more likely to continue...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics